Cearnal Martin E 4
4 · CUMBERLAND PHARMACEUTICALS INC · Filed Jan 7, 2022
Insider Transaction Report
Form 4
Cearnal Martin E
Director
Transactions
- Purchase
Common Stock
2021-12-01$4.14/sh+90$373→ 176,449 total - Purchase
Common Stock
2021-12-02$3.84/sh+90$346→ 176,539 total - Purchase
Common Stock
2021-12-03$4.47/sh+90$402→ 176,629 total - Purchase
Common Stock
2021-12-06$4.46/sh+90$401→ 176,719 total - Purchase
Common Stock
2021-12-07$5.61/sh+90$505→ 176,809 total - Purchase
Common Stock
2021-12-08$6.15/sh+90$554→ 176,899 total - Purchase
Common Stock
2021-12-09$5.81/sh+90$523→ 176,989 total - Purchase
Common Stock
2021-12-10$4.82/sh+90$434→ 177,079 total - Purchase
Common Stock
2021-12-13$4.36/sh+200$872→ 177,279 total - Purchase
Common Stock
2021-12-14$4.28/sh+200$856→ 177,479 total - Purchase
Common Stock
2021-12-15$4.29/sh+200$858→ 177,679 total - Purchase
Common Stock
2021-12-16$4.53/sh+240$1,087→ 177,919 total - Purchase
Common Stock
2021-12-17$4.17/sh+240$1,001→ 178,159 total - Purchase
Common Stock
2021-12-20$4.33/sh+314$1,360→ 178,473 total
Footnotes (1)
- [F1]The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.